专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08492334B2 Sustained intraocular delivery of drugs from biodegradable polymeric microparticles 有权
标题翻译：从可生物降解的聚合物微粒中持续的眼内输送药物
公开(公告)号：US08492334B2
公开(公告)日：2013-07-23
申请号：US12664792
申请日：2008-06-18
申请人： Erin Lavik , Young H. Kwon , Markus Kuehn , Sandeep Saluja , James Bertram , John Huang
发明人： Erin Lavik , Young H. Kwon , Markus Kuehn , Sandeep Saluja , James Bertram , John Huang
IPC分类号： A61K38/18 , A61K38/22 , A61K31/7036 , A61K31/704 , A61K31/57 , A61K31/573
CPC分类号： A61K9/1647 , A61K9/0048 , A61K9/5153
摘要： Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing one or more diseases or disorders of the eye, and methods of making and using thereof, are described. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (IOP) in the eye. Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time.
摘要翻译：描述了包含一种或多种活性剂，特别是可用于治疗或预防一种或多种眼睛疾病或病症的活性剂的生物降解性聚合物微粒组合物及其制备和使用方法。在优选的实施方案中，微粒组合物含有一种或多种用于治疗眼中升高的眼内压（IOP）的活性剂。相对亲水的，优选羧化的聚合物材料如PLGA用于药物，例如相对水溶性的马来酸噻吗洛尔，以增加药物负荷。使用较高分子量的聚合物，以及LA（其具有较长的降解时间，长达一至两年）与GA（其具有短的降解时间，短至几天至一周）的比率被使用提供更长时间的释放。

2. 发明申请

US20100261646A1 SUSTAINED INTRAOCULAR DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES 有权
标题翻译：从生物可降解的聚合物微生物中持续的药物输送
公开(公告)号：US20100261646A1
公开(公告)日：2010-10-14
申请号：US12664792
申请日：2008-06-18
申请人： Erin Lavik , Young H. Kwon , Markus Kuehn , Sandeep Saluja , James Bertram , John Huang
发明人： Erin Lavik , Young H. Kwon , Markus Kuehn , Sandeep Saluja , James Bertram , John Huang
IPC分类号： A61K38/18 , A61K31/704 , A61K31/7036 , A61K31/57 , A61K31/573 , A61K31/5365 , A61K31/5377 , A61K31/496 , A61K31/505 , A61K31/4709 , A61K31/47 , A61K31/222 , A61K31/138
CPC分类号： A61K9/1647 , A61K9/0048 , A61K9/5153
摘要： Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”). Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time. The combination of drug loading and release rate, as well as the minimization of initial burst release, result in prolonged release of a higher amount of drug.
摘要翻译：描述了包含一种或多种活性剂，特别是可用于治疗或预防或一种或多种眼睛疾病或障碍的活性剂的生物可降解聚合物微粒组合物及其制备和使用方法。微球组合物在体内释放有效量的一种或多种活性剂大于14天，体内优选大于60天，更优选体内至多73天，更优选在体内释放大于90天，甚至更优选在体内超过100天，最优选在体内大于107天。在优选的实施方案中，微粒组合物含有一种或多种用于管理眼中升高的眼内压（TOP）的活性剂。在一个实施方案中，微球由聚丙交酯 - 共 - 乙交酯（“PLGA”）形成; 在另一个实施方案中，微球由共混PLGA和聚乳酸（“PLA”）形成。相对亲水的，优选羧化的聚合物材料如PLGA用于药物，例如相对水溶性的马来酸噻吗洛尔，以增加药物负荷。使用较高分子量的聚合物，以及LA（其具有较长的降解时间，长达一至两年）与GA（其具有短的降解时间，短至几天至一周）的比率被使用提供更长时间的释放。药物负载和释放速率的组合以及初始爆发释放的最小化导致更长量的药物释放。

3. 发明授权

US09107258B1 LED controller 有权
标题翻译： LED控制器
公开(公告)号：US09107258B1
公开(公告)日：2015-08-11
申请号：US13178336
申请日：2011-07-07
申请人： Thomas Chao , John Huang
发明人： Thomas Chao , John Huang
IPC分类号： H05B37/02 , H05B33/08
CPC分类号： H05B33/0815 , H05B33/083 , Y02B20/341
摘要： Methods and circuits for controlling LEDs are disclosed. In one embodiment, the light emitting diode (LED) integrated circuit controller includes a voltage regulator circuit configured to operate with an alternating current (AC) power source, where the voltage regulator circuit includes a depletion device configured to receive a varying AC voltage and to generate a unregulated voltage, and a band gap voltage reference circuit configured to received the unregulated voltage and to generate a substantially constant direct current (DC) voltage. The LED integrated circuit controller further includes a current setting circuit configured to receive the substantially constant DC voltage and to provide a substantially constant direct current to drive a series of light emitting diodes, and a second depletion device configured to protect the LED integrated circuit controller from external high voltages.
摘要翻译：公开了用于控制LED的方法和电路。在一个实施例中，发光二极管（LED）集成电路控制器包括配置成与交流（AC）电源一起工作的电压调节器电路，其中电压调节器电路包括被配置为接收变化的AC电压的耗尽装置，产生未调节的电压，以及带隙电压参考电路，被配置为接收未调节的电压并产生基本恒定的直流（DC）电压。 LED集成电路控制器还包括电流设置电路，其被配置为接收基本上恒定的DC电压并提供基本上恒定的直流电流以驱动一系列发光二极管;以及第二耗尽器件，被配置为保护LED集成电路控制器外部高电压。

4. 发明申请

US20060089855A1 Medication management system 审中-公开
公开(公告)号：US20060089855A1
公开(公告)日：2006-04-27
申请号：US10783792
申请日：2004-02-20
申请人： Geoffrey Holland , Patrick Keely , Jeff Pelletier , John Huang
发明人： Geoffrey Holland , Patrick Keely , Jeff Pelletier , John Huang
IPC分类号： G06Q10/00
CPC分类号： G06Q50/22 , G06F19/326 , G06F19/3456 , G06Q10/10 , G16H10/60 , G16H40/63 , G16H50/20
摘要： A medication management system (MMS) includes a medication management unit (MMU) associated with a medical device. The MMU downloads a medication order to the medical device only if information from a first input matches information from a second input. The medical device receives delivery information only from the MMU. The medication order is performed only after delivery data validation. The MMU also determines drug-drug incompatibility. The MMU can modulate (start, stop, and dynamically adjust) medication order performance. The medical device wirelessly receives a patient ID to automatically associate with the patient. During delivery, the medical device caches an updated drug library to replace an existing one. The medical device displays a patient picture for validation. The MMU evaluates the performance of medical devices and caregivers based medical device feedback. The MMU adjusts the output of medical device information conveyed to a caregiver.

5. 发明授权

US06552889B1 Current limiting technique for hybrid power MOSFET circuits 有权
标题翻译：混合功率MOSFET电路的限流技术
公开(公告)号：US06552889B1
公开(公告)日：2003-04-22
申请号：US09908178
申请日：2001-07-17
申请人： John Huang , Hamza Yilmaz , Mohamed N. Darwish , Wharton McDaniel , Kyle Terrill , Peter Tu Dang
发明人： John Huang , Hamza Yilmaz , Mohamed N. Darwish , Wharton McDaniel , Kyle Terrill , Peter Tu Dang
IPC分类号： H02H300
CPC分类号： H03K17/0822
摘要： A power FET and a replica FET on a semiconductor chip coupled to a logic control circuit on a second semiconductor chip within a single housing. A power FET and a scaled down replica of the power FET are disposed on a semiconductor chip. The power FET is used as a switch to couple a DC power source to a load. A fraction of the power FET drain current passes through the replica FET and an external resistance. When the voltage across the external resistance exceeds a maximum value based upon the maximum allowable power FET drain current, the logic control circuit enters into a pulsed gate (PG) mode of operation. The first step in the PG mode is to switch both FETs into a non-conducting state for a predefined period of time. After this time period, a ramp voltage applied between gate and source of both FETs will switch them back into a current conducting state while holding the power FET drain current below its upper limit in the presence of a high capacitance load. If the voltage across the external resistance increases above the maximum, the PG mode of operation continues. PG mode of operation ceases and normal operation follows when the external resistance voltage remains below the established maximum. The combination of predefined nonconducting time and maximum drain current ensures operation of the power FET below maximum power dissipation limits. The PG mode of operation eliminates the need for additional temperature and thermal control circuits.
摘要翻译：半导体芯片上的功率FET和复制FET耦合到单个壳体内的第二半导体芯片上的逻辑控制电路。功率FET的功率FET和缩小的复制品设置在半导体芯片上。功率FET用作将直流电源耦合到负载的开关。功率FET漏极电流的一部分通过复制FET和外部电阻。当外部电阻两端的电压超过最大容许功率FET漏极电流的最大值时，逻辑控制电路进入脉冲门（PG）工作模式。 PG模式的第一步是将两个FET切换到非导通状态一段预定的时间。在这个时间段之后，施加在两个FET的栅极和源极之间的斜坡电压将在高电容负载存在的同时将功率FET漏极电流保持在其上限以下，将其切换回导通状态。如果外部电阻两端的电压增加到最大值以上，则PG模式继续。当外部电阻保持低于建立的最大值时，PG模式停止，正常操作。预定义的非导通时间和最大漏极电流的组合确保功率FET的功耗低于最大功耗限制。 PG操作模式无需额外的温度和热控制电路。

6. 发明申请

US20230055181A1 UNIVERSAL WHEEL-FIXATION FRAME FOR ELECTRONIC ALIGNMENT SENSOR 有权
公开(公告)号：US20230055181A1
公开(公告)日：2023-02-23
申请号：US17890729
申请日：2022-08-18
申请人： John Huang
发明人： John Huang
IPC分类号： G01B5/255
摘要： An alignment frame for affixing a sensor configured to measure one or more alignment angles to a wheel of a vehicle can include a pair of arms configured to contact a tire mounted on the wheel to support the alignment frame, a center base configured to receive a first bar, a second bar, and a third bar orthogonally aligned in a linear alignment such that the first bar is at ninety degrees from the horizontal axis defined by the second and the third bar, and a spacer positioned on each of the first, second, and third bars and configured to align the bars with a face of the rim so as to center the center base with respect to the rim of the wheel. The center base can receive a mounting portion of the sensor to center the sensor with the respect to the rim of the wheel.

7. 发明申请

US20080007888A1 Micro-electro-mechanical system (MEMS) variable capacitors and actuation components and related methods 有权
标题翻译：微机电系统（MEMS）可变电容器及其驱动元件及相关方法
公开(公告)号：US20080007888A1
公开(公告)日：2008-01-10
申请号：US11715676
申请日：2007-03-08
申请人： Arthur Morris , John Huang
发明人： Arthur Morris , John Huang
IPC分类号： H01G5/16
CPC分类号： H03H7/38 , H01G4/38 , H01G5/18 , H03H7/463
摘要： Micro-electro-mechanical system (MEMS) variable capacitors and actuation components and related methods are provided. A MEMS variable capacitor can include first and second feed lines extending substantially parallel to one another. Further, MEMS variable capacitors can include first and second capacitive plates being spaced apart from the first and second feed lines. The first and second capacitive plates can be separately movable with respect to at least one of the first and second feed lines for varying the capacitance between the first and second feed lines over a predetermined capacitance range.
摘要翻译：提供了微电机械系统（MEMS）可变电容器和致动部件及相关方法。 MEMS可变电容器可以包括基本上彼此平行延伸的第一和第二馈送线。此外，MEMS可变电容器可以包括与第一和第二馈电线间隔开的第一和第二电容板。第一和第二电容板可以相对于第一和第二馈电线中的至少一个分别移动，以在预定电容范围内改变第一和第二馈电线之间的电容。

8. 发明授权

US09286369B2 Data replication across enterprise boundaries 有权
标题翻译：跨企业边界的数据复制
公开(公告)号：US09286369B2
公开(公告)日：2016-03-15
申请号：US12649829
申请日：2009-12-30
申请人： Mingliang Pei , Oanh Hoang , Ruiping Sun , John Huang
发明人： Mingliang Pei , Oanh Hoang , Ruiping Sun , John Huang
IPC分类号： G06F17/30
CPC分类号： G06F17/30581
摘要： Systems and methods for synchronizing verification data in a distributed database including client and server databases. The server database may exchange verification data regarding one-time passwords to multiple client databases. An update to the server database may be initiated based on information stored in the client database by pushing updated verification information from the client database to the server database via an SSL tunnel. An update to the client database may be initiated based on information stored in the server database by pulling updated verification data from the server database to the client database via an SSL tunnel. The client database and the server database may include a two-dimensional data field including the verification data and an associated key identifier, and a site ID. The site ID may include a unique identifier to identify the respective database in which it is included. The data field may include a sequence number assigned to each row of data that increases every time the row of information is updated. The client database and the server database may also include a replication tracking table including a record of the last known update to a remote database. Data fields that require updating may be determined based on the site ID and a comparison of the sequence numbers from the replication tracking table and the server's database.
摘要翻译：用于在包括客户端和服务器数据库的分布式数据库中同步验证数据的系统和方法。服务器数据库可以将关于一次性密码的验证数据交换到多个客户数据库。可以基于通过SSL隧道将更新的验证信息从客户端数据库推送到服务器数据库，基于存储在客户端数据库中的信息来启动对服务器数据库的更新。可以基于存储在服务器数据库中的信息，通过经由SSL隧道将更新的验证数据从服务器数据库拉到客户端数据库来启动对客户端数据库的更新。客户端数据库和服务器数据库可以包括包括验证数据和相关联的密钥标识符的二维数据字段以及站点ID。站点ID可以包括用于标识其中包括其的相应数据库的唯一标识符。数据字段可以包括分配给每次更新信息行时每增加一行数据的序列号。客户端数据库和服务器数据库还可以包括复制跟踪表，其包括对远程数据库的最后已知更新的记录。需要更新的数据字段可以基于站点ID和来自复制跟踪表和服务器数据库的序列号的比较来确定。

9. 发明申请

US20150154183A1 Auto-translation for multi user audio and video 有权
公开(公告)号：US20150154183A1
公开(公告)日：2015-06-04
申请号：US13316689
申请日：2011-12-12
申请人： Trausti Kristjansson , John Huang , Yu-Kuan Lin , Hung-ying Tyan , Jakob David Uszkoreit , Joshua James Estelle , Chung-yi Wang , Kirill Buryak , Yusuke Konishi
发明人： Trausti Kristjansson , John Huang , Yu-Kuan Lin , Hung-ying Tyan , Jakob David Uszkoreit , Joshua James Estelle , Chung-yi Wang , Kirill Buryak , Yusuke Konishi
IPC分类号： G06F17/28 , G10L15/26 , G10L13/00
CPC分类号： G06F17/289 , G10L13/00 , G10L15/26 , H04M3/56 , H04M3/568 , H04M2203/2061 , H04M2242/12 , H04N7/15 , H04N7/152
摘要： The disclosed subject matter provides a system, computer readable storage medium, and a method providing an audio and textual transcript of a communication. A conferencing services may receive audio or audio visual signals from a plurality of different devices that receive voice communications from participants in a communication, such as a chat or teleconference. The audio signals representing voice (speech) communications input into respective different devices by the participants. A translation services server may receive over a separate communication channel the audio signals for translation into a second language. As managed by the translation services server, the audio signals may be converted into textual data. The textual data may be translated into text of different languages based the language preferences of the end user devices in the teleconference. The translated text may be further translated into audio signals.

10. 发明申请

US20100016209A1 Methods of Reducing Side Effects in Cancer Therapy 审中-公开
标题翻译：减少癌症治疗副作用的方法
公开(公告)号：US20100016209A1
公开(公告)日：2010-01-21
申请号：US12096152
申请日：2006-12-07
申请人： John Huang , Ding Chang , Fengping Shan , Shi-Lung Lo
发明人： John Huang , Ding Chang , Fengping Shan , Shi-Lung Lo
IPC分类号： A61K38/03 , A61P35/00
CPC分类号： A61K38/33
摘要： The present invention provides a method of decreasing side effects in a human or animal cancer patient due to radiation therapy or chemotherapy. With this method, methionine enkephalin is administered to the patient at least one time per week for a first time period, where the first time period is at least three weeks. In one embodiment, the first time period is one or two months. Methionine enkephalin is then administered to the patient one time per month for a second time period, where the second time period is at least one month, and where the second time period is consecutive to the first time period. In one embodiment, the total term of methionine enkephalin treatment is at least six months. Methionine enkephalin may be administered to the patient at the same time as, before, or after administration of radiation or chemotherapy.
摘要翻译：本发明提供了减少由于放射治疗或化疗引起的人或动物癌症患者的副作用的方法。使用这种方法，蛋氨酸脑啡肽每周至少一次给予患者第一个时间段，其中第一时间段至少为三周。在一个实施例中，第一时间段是一个或两个月。然后将甲硫氨酸脑啡肽每月一次施用给患者第二时间段，其中第二时间段至少为一个月，第二时间段连续到第一时间段。在一个实施方案中，甲硫氨酸脑啡肽治疗的总期限为至少6个月。甲硫氨酸脑啡肽可以在给予放射或化疗的同时，之前或之后施用于患者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式